Yahoo
Shanghai - Delayed Quote CNY

Tasly Pharmaceutical Group Co., Ltd (600535.SS)

13.82 +0.21 (+1.54%)
At close: October 30 at 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 600535.SS
  • Previous Close 13.61
  • Open 13.50
  • Bid 13.82 x --
  • Ask 13.83 x --
  • Day's Range 13.50 - 13.95
  • 52 Week Range 12.90 - 16.24
  • Volume 13,316,949
  • Avg. Volume 13,631,322
  • Market Cap (intraday) 20.646B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) 16.85
  • EPS (TTM) 0.82
  • Earnings Date --
  • Forward Dividend & Yield 0.34 (2.46%)
  • Ex-Dividend Date Oct 15, 2026
  • 1y Target Est 16.99

Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceutical Co., Ltd. and changed its name to Tasly Pharmaceutical Group Co., Ltd in May 2012. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.

www.taslypharma.com

10,563

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600535.SS
6.05%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

600535.SS
6.97%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

600535.SS
2.36%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

600535.SS
18.44%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY25
Revenue 2.02B
Earnings --
Profit Margin 0.00%

Q2

FY24

Q1

FY25

Q2

FY25

Q3

FY25

0
500M
1B
2B
2B
0.0%

Analyst Insights

View More

Analyst Price Targets

14.80
16.99 Average
13.82 Current
18.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.29%

  • Return on Assets (ttm)

    7.19%

  • Return on Equity (ttm)

    9.05%

  • Revenue (ttm)

    8B

  • Net Income Avi to Common (ttm)

    1.22B

  • Diluted EPS (ttm)

    0.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.7B

  • Total Debt/Equity (mrq)

    1.40%

  • Levered Free Cash Flow (ttm)

    1.35B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: